Spectrum Chemical Strikes Buffers Distribution Deal with ANGUS Chemical Company
The deal will see Spectrum market and distribute ANGUS’ biologics grade buffers in the United States and Canada.
Spectrum Chemical, a provider of fine chemicals, laboratory equipment, and supplies, announced a new distribution arrangement on June 9, 2022 with ANGUS Chemical Company, a specialty ingredients manufacturer. The deal will see Spectrum market and distribute ANGUS’ tris(hydroxymethyl)aminomethane (TRIS) buffers in the United States and Canada.
According to a company press release, Spectrum will work with the TRIS AMINO Advanced Crystal and BIS-TRIS biologics grade buffers. These products are used as buffering agents in cell culture and bioprocessing applications and in the purification of biological molecules in downstream processing.
“The addition of these essential ANGUS-branded TRIS and TRIS derivative products to our product offering broadens our capability to deliver best-in-class solutions to our biopharmaceutical and life sciences research customers,” said Jim Luchsinger, vice-president, business development, Spectrum Chemical, in the press release. “We are committed to delivering the fullest range of high-quality chemicals necessary for every bioprocessing stage, from development through commercialization.”
“Through Spectrum Chemical’s deep experience in serving the U.S. and Canadian research markets, we look forward to enhancing our supply and delivery capabilities for customers in the region supported by ANGUS’ commitment to providing 100% traceability and the most secure, sustainable supply of these essential chemistries,” said Doug Ward, North American sales director, ANGUS, in the press release.
Source: Spectrum Chemical
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
